Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-414 placebo-controlled pediatric immunogenicity and safety study
jRCT2031220598Completed
- Sponsor
- KM Biologics
- Start
- Jan 2023
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing KD-414 with Placebo (2 arms). Primary endpoints: Geometric mean neutralizing antibody titer, Seroconversion rate of neutralizing antibodies and 6 more. Started Jan 2023; status: completed.
02
Drugs
KD-414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220598.